Alpha DNA Investment Management LLC Takes Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Alpha DNA Investment Management LLC purchased a new stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 5,127 shares of the medical equipment provider’s stock, valued at approximately $412,000.

Several other hedge funds have also added to or reduced their stakes in the company. UMB Bank n.a. boosted its stake in shares of Lantheus by 161.4% in the 1st quarter. UMB Bank n.a. now owns 400 shares of the medical equipment provider’s stock valued at $25,000 after purchasing an additional 247 shares during the last quarter. GAMMA Investing LLC grew its holdings in Lantheus by 184.1% during the 2nd quarter. GAMMA Investing LLC now owns 321 shares of the medical equipment provider’s stock worth $26,000 after acquiring an additional 208 shares during the period. Principal Securities Inc. bought a new stake in shares of Lantheus during the 4th quarter valued at $28,000. Fidelis Capital Partners LLC acquired a new position in shares of Lantheus in the 1st quarter valued at $34,000. Finally, FinTrust Capital Advisors LLC boosted its position in shares of Lantheus by 53.6% in the 1st quarter. FinTrust Capital Advisors LLC now owns 665 shares of the medical equipment provider’s stock worth $41,000 after purchasing an additional 232 shares during the last quarter. Institutional investors own 99.06% of the company’s stock.

Insider Activity

In related news, Director Gerard Ber sold 15,500 shares of the stock in a transaction on Monday, August 12th. The shares were sold at an average price of $96.48, for a total transaction of $1,495,440.00. Following the completion of the transaction, the director now owns 21,221 shares in the company, valued at $2,047,402.08. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, President Paul Blanchfield sold 2,000 shares of the stock in a transaction dated Thursday, August 8th. The shares were sold at an average price of $96.39, for a total transaction of $192,780.00. Following the completion of the transaction, the president now directly owns 98,980 shares in the company, valued at approximately $9,540,682.20. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director Gerard Ber sold 15,500 shares of the stock in a transaction dated Monday, August 12th. The stock was sold at an average price of $96.48, for a total transaction of $1,495,440.00. Following the transaction, the director now owns 21,221 shares of the company’s stock, valued at $2,047,402.08. The disclosure for this sale can be found here. Insiders have sold 40,852 shares of company stock worth $3,922,001 over the last ninety days. Insiders own 1.50% of the company’s stock.

Lantheus Trading Down 3.4 %

LNTH opened at $107.95 on Thursday. The firm’s fifty day simple moving average is $104.87 and its 200 day simple moving average is $85.24. The stock has a market capitalization of $7.49 billion, a P/E ratio of 16.48 and a beta of 0.50. The company has a current ratio of 4.68, a quick ratio of 4.41 and a debt-to-equity ratio of 0.55. Lantheus Holdings, Inc. has a 12 month low of $50.20 and a 12 month high of $126.89.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings data on Wednesday, July 31st. The medical equipment provider reported $1.61 earnings per share for the quarter, missing the consensus estimate of $1.68 by ($0.07). The firm had revenue of $394.10 million for the quarter, compared to analyst estimates of $382.12 million. Lantheus had a return on equity of 48.36% and a net margin of 29.80%. The firm’s quarterly revenue was up 22.5% on a year-over-year basis. During the same period in the prior year, the company earned $1.40 earnings per share. As a group, research analysts anticipate that Lantheus Holdings, Inc. will post 5.99 EPS for the current fiscal year.

Analysts Set New Price Targets

LNTH has been the topic of several analyst reports. JMP Securities cut their target price on Lantheus from $130.00 to $125.00 and set a “market outperform” rating on the stock in a research note on Thursday, August 1st. B. Riley lifted their price objective on shares of Lantheus from $105.00 to $146.00 and gave the stock a “buy” rating in a research note on Thursday, July 25th. Redburn Atlantic assumed coverage on shares of Lantheus in a research note on Tuesday, September 3rd. They issued a “buy” rating and a $175.00 target price for the company. Leerink Partners increased their target price on shares of Lantheus from $106.00 to $127.00 and gave the stock an “outperform” rating in a report on Thursday, July 11th. Finally, Truist Financial decreased their price target on shares of Lantheus from $141.00 to $135.00 and set a “buy” rating for the company in a report on Thursday, August 1st. Two equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $126.00.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.